Get all your news in one place.
100's of premium titles.
One app.
Start reading
Barchart
Barchart
Larry Ramer

uniQure Stock Looks Drastically Undervalued After Upbeat FDA Meeting

After the FDA adopted a more positive stance towards uniQure's (QURE) gene therapy for Huntington's Disease, AMT-130, the agency is likely to approve the biologic treatment. As a result, QURE stock is dramatically undervalued compared with its long-term potential. However, it still poses a significant risk, making it a buy for long-term growth investors with a meaningful tolerance for risk.

www.barchart.com
Sign up to read this article
Read news from 100's of titles, curated specifically for you.
Already a member? Sign in here
Related Stories
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member? Sign in here
Our Picks
Fourteen days free
Download the app
One app. One membership.
100+ trusted global sources.